--- id: wiki-2026-0508-neuropharmacology-of-substance-u title: Neuropharmacology of Substance Use Disorders category: 10_Wiki/Topics status: needs_review canonical_id: self aliases: [P-Reinforce-AUTO-NPSUD-001] duplicate_of: none source_trust_level: A confidence_score: 0.95 tags: [auto-reinforced, pharmacology, addiction, neurotransmitters] raw_sources: [] last_reinforced: 2026-04-20 github_commit: pending inferred_by: Claude Opus 4.7 (auto-normalize 2026-05-08) --- # [[Neuropharmacology of Substance Use Disorders|Neuropharmacology of Substance Use Disorders]] ## ๐Ÿ“Œ ํ•œ ์ค„ ํ†ต์ฐฐ (The Karpathy Summary) > "๋‡Œ์˜ ํ†ต์‹ ๋ง์„ ๋งˆ๋น„์‹œํ‚ค๋Š” ๊ฐ€์งœ ์‹ ํ˜ธํƒ„: ์™ธ๋ถ€ ์•ฝ๋ฌผ์ด ์‹ ๊ฒฝ์ „๋‹ฌ๋ฌผ์งˆ ์ˆ˜์šฉ์ฒด๋ฅผ ๊ฐ•์ œ๋กœ ์ ์œ ํ•˜์—ฌ ์ƒ์กด ๋ณด์ƒ ์‹œ์Šคํ…œ์„ ๋ถ•๊ดด์‹œํ‚ค๋Š” ํ™”ํ•™์  ํ•˜์ด์žฌํ‚น." ## ๐Ÿ“– ๊ตฌ์กฐํ™”๋œ ์ง€์‹ (Synthesized Content) ๋ฌผ์งˆ ์‚ฌ์šฉ ์žฅ์• ์˜ ์‹ ๊ฒฝ์•ฝ๋ฆฌํ•™(Neuropharmacology of SUD)์€ ์ค‘๋…์„ฑ ๋ฌผ์งˆ์ด ๋‡Œ์˜ ์‹œ๋ƒ…์Šค ์ˆ˜์ค€์—์„œ ์–ด๋–ป๊ฒŒ ์ž‘์šฉํ•˜๋ฉฐ, ํ–‰๋™ ์žฅ์• ๋ฅผ ์œ ๋ฐœํ•˜๋Š”์ง€ ์—ฐ๊ตฌํ•ฉ๋‹ˆ๋‹ค. 1. **์•ฝ๋ฌผ๊ตฐ๋ณ„ ์ž‘์šฉ ๊ธฐ์ œ**: * **์ž๊ทน์ œ (Cocaine, Amphetamine)**: ์‹œ๋ƒ…์Šค ํ‹ˆ์ƒˆ์˜ ๋„ํŒŒ๋ฏผ ์žฌํก์ˆ˜๋ฅผ ์ฐจ๋‹จํ•˜๊ฑฐ๋‚˜ ๋ฐฉ์ถœ์„ ์ด‰์ง„ํ•˜์—ฌ ๋ณด์ƒ ์‹ ํ˜ธ๋ฅผ ํญ์ฃผ ์‹œํ‚ด. * **์ง„์ •์ œ/์•„ํŽธ๋ฅ˜ (Opioids)**: ๋‡Œ ๋‚ด ์ฒœ์—ฐ ํ†ต์ฆ ์กฐ์ ˆ ๋ฌผ์งˆ(Endorphin) ์ˆ˜์šฉ์ฒด์— ๊ฒฐํ•ฉํ•˜์—ฌ ์พŒ๋ฝ์„ ์œ ๋„ํ•˜๊ณ  ์–ต์ œ์„ฑ ์‹ ํ˜ธ๋ฅผ ๊ฐ•ํ™”. * **์•Œ์ฝ”์˜ฌ**: GABA(์–ต์ œ)๋ฅผ ๊ฐ•ํ™”ํ•˜๊ณ  Glutamate(ํฅ๋ถ„)๋ฅผ ์–ต์ œํ•˜์—ฌ ๋‡Œ ํ™œ๋™ ์ „๋ฐ˜์„ ๋‘”ํ™”์‹œํ‚ด. 2. **๋‚ด์„ฑ๊ณผ ๊ธˆ๋‹จ (Tolerance & Withdrawal)**: * **Down-regulation**: ์ง€์†์ ์ธ ๊ณผ์ž‰ ์ž๊ทน์— ๋Œ€์‘ํ•˜๊ธฐ ์œ„ํ•ด ๋‡Œ๊ฐ€ ์Šค์Šค๋กœ ์ˆ˜์šฉ์ฒด ์ˆ˜๋ฅผ ์ค„์ด๊ฑฐ๋‚˜ ๋ฏผ๊ฐ๋„๋ฅผ ๋‚ฎ์ถค. * **Inverted Reward Profile**: ํ‰์†Œ์—๋Š” ์•„๋ฌด๋Ÿฐ ์ฆ๊ฑฐ์›€์„ ๋А๋ผ์ง€ ๋ชปํ•˜๊ณ , ์˜ค์ง ์•ฝ๋ฌผ์ด ์žˆ์„ ๋•Œ๋งŒ '์ •์ƒ' ์ƒํƒœ๋กœ ๋А๊ปด์ง€๋Š” ์ƒํƒœ๋กœ ๊ณ ์ฐฉ. ## โš ๏ธ ๋ชจ์ˆœ ๋ฐ ์—…๋ฐ์ดํŠธ (Contradictions & Updates) - **๊ณผ๊ฑฐ ๋ฐ์ดํ„ฐ์™€์˜ ์ถฉ๋Œ**: ๊ณผ๊ฑฐ์—๋Š” ์ค‘๋…์„ '์˜์ง€ ๋ถ€์กฑ'์œผ๋กœ ์น˜๋ถ€ํ–ˆ์œผ๋‚˜, ์•ฝ๋ฆฌํ•™์  ์ฆ๊ฑฐ๋“ค์€ ์ด๊ฒƒ์ด ์ „์ „๋‘์—ฝ๊ณผ ๋ณ€์—ฐ๊ณ„ ์‚ฌ์ด์˜ ํ™”ํ•™์  ํ†ต์ œ๊ถŒ์ด ์™„์ „ํžˆ ์ƒ์‹ค๋œ '๋ฌผ๋ฆฌ์  ๊ณ ์žฅ'์ž„์„ ์ž…์ฆํ•จ. - **์ •์ฑ… ๋ณ€ํ™”(RL Update)**: ์ตœ๊ทผ์—๋Š” ์ค‘๋…์„ '์‹ ๊ฒฝ๋ง์˜ ๊ฐ€์ค‘์น˜๊ฐ€ ํŠน์ • ๋ฐฉํ–ฅ์œผ๋กœ ๋ฐœ์‚ฐ(Exploding Gradient)ํ•œ ์ƒํƒœ'๋กœ ํ•ด์„ํ•˜์—ฌ, ์ด๋ฅผ ๋‹ค์‹œ ์•ˆ์ •ํ™”์‹œํ‚ค๊ธฐ ์œ„ํ•œ ์•ฝ๋ฌผ-ํ–‰๋™ ๊ฒฐํ•ฉ ์น˜๋ฃŒ ๋ชจ๋ธ(Pharmacotherapy-assisted CBT)์ด ํ‘œ์ค€์œผ๋กœ ์ž๋ฆฌ์žก์Œ. ## ๐Ÿ”— ์ง€์‹ ์—ฐ๊ฒฐ (Graph) - **Related**: Neurobiology of Reward, [[Dopamine|Dopamine]], [[Neuroplasticity in Addiction|Neuroplasticity in Addiction]], Psychopharmacology - **Modern Tech/Tools**: PET (Positron Emission Tomography), MAT (Medication-Assisted Treatment). --- ## ๐Ÿค– LLM ํ™œ์šฉ ํžŒํŠธ (How to Use This Knowledge) **์–ธ์ œ ์ด ์ง€์‹์„ ์“ฐ๋Š”๊ฐ€:** - *(TODO)* **์–ธ์ œ ์“ฐ๋ฉด ์•ˆ ๋˜๋Š”๊ฐ€:** - *(TODO)* ## ๐Ÿงช ๊ฒ€์ฆ ์ƒํƒœ (Validation) - **์ •๋ณด ์ƒํƒœ:** needs_review - **์ถœ์ฒ˜ ์‹ ๋ขฐ๋„:** A - **๊ฒ€ํ†  ์ด์œ :** *(P-Reinforce Phase 1 ์ž๋™ ์ •๊ทœํ™”. ๋ณธ๋ฌธ ๊ฒ€์ฆ ํ•„์š”.)* ## ๐Ÿงฌ ์ค‘๋ณต ๊ฒ€์‚ฌ (Duplicate Check) - **๊ธฐ์กด ์œ ์‚ฌ ๋ฌธ์„œ:** *(TODO: ์ธ๋ฑ์„œ ํด๋Ÿฌ์Šคํ„ฐ ๋ฆฌํฌํŠธ ์ฐธ์กฐ)* - **์ฒ˜๋ฆฌ ๋ฐฉ์‹:** UPDATE (์ž๋™ ์ •๊ทœํ™”) - **์ฒ˜๋ฆฌ ์ด์œ :** Phase 1 ์ •๊ทœํ™” โ€” ์˜› ํ…œํ”Œ๋ฆฟ/๋ˆ„๋ฝ ํ•„๋“œ ๋ณด๊ฐ•. ## ๐Ÿ•“ ๋ณ€๊ฒฝ ์ด๋ ฅ (Changelog) | ๋‚ ์งœ | ๋ณ€๊ฒฝ ๋‚ด์šฉ | ์ฒ˜๋ฆฌ ๋ฐฉ์‹ | ์‹ ๋ขฐ๋„ | |------|-----------|-----------|--------| | 2026-05-08 | P-Reinforce Phase 1 ์ •๊ทœํ™” (frontmatter + ํ—ค๋” ํ‘œ์ค€ํ™”) | UPDATE | A |